Children’s Hospital to Lead Immunotherapy Study – Los Angeles Business Journal
Los Angeles Business Journal |
Children’s Hospital to Lead Immunotherapy Study
Los Angeles Business Journal … the Program for Cell Enhancement and Technologies for Immunotherapy at the Children’s National Health System. Health business reporter Dana Bartholomew can be reached at dbartholomew@labusinessjournal.com. Follow him on Twitter @_DanaBart. |
Medical Xpress |
Stem cells pave the way for new treatment of diabetes
Medical Xpress A new stem cell study conducted at the University of Copenhagen shows how we may increase the vital production of insulin in patients suffering from diabetes. The discovery helps to more efficiently at less cost make insulin-producing beta cells from … Global Stem Cell Storage Market – Positive long-term growth outlook 2017-2022Medgadget (blog) Global Stem Cell Media Market 2018-2023: Thermo Fisher, STEMCELL Technologies and Merck MilliporeHitechexaMiner (press release) Diabetes’ days are numberedInnovators Magazine satPRnews (press release) –PostObserver all 19 news articles » |
Muscular Dystrophy News |
FDA Clears IND Application for GALGT2 Gene Therapy for Duchenne Muscular Dystrophy
Muscular Dystrophy News The U.S. Food and Drug Administration (FDA) recently cleared an investigational new drug (IND) application for the GALGT2 gene therapy program for Duchenne muscular dystrophy (DMD) filed by Sarepta Therapeutics and Nationwide Children’s Hospital. Sarepta Therapeutics (SRPT): FDA Clears GALGT2 Gene Therapy Program – William BlairStreetInsider.com Sarepta Therapeutics and Nationwide Children’s Hospital Announce FDA Clearance of IND for Micro-Dystrophin Gene …Markets Insider Sarepta Therapeutics And Nationwide Children’s Hospital Announce US Food And Drug Administration (FDA …Clinical Leader |
Muscular Dystrophy News |
FDA Clears IND Application for GALGT2 Gene Therapy for Duchenne Muscular Dystrophy
Muscular Dystrophy News The U.S. Food and Drug Administration (FDA) recently cleared an investigational new drug (IND) application for the GALGT2 gene therapy program for Duchenne muscular dystrophy (DMD) filed by Sarepta Therapeutics and Nationwide Children’s Hospital. Sarepta Therapeutics (SRPT): FDA Clears GALGT2 Gene Therapy Program – William BlairStreetInsider.com Sarepta Therapeutics and Nationwide Children’s Hospital Announce FDA Clearance of IND for Micro-Dystrophin Gene …Markets Insider Sarepta Therapeutics And Nationwide Children’s Hospital Announce US Food And Drug Administration (FDA …Clinical Leader |
PLoS Blogs (blog) |
PLOS iGEM 2017 – sign up now open!
PLoS Blogs (blog) Inspired by Biotreks, a synthetic biology journal for high schoolers, the Realtime Peer Review Jamboree was a live online event where authors and reviewers could comment and discuss iGEM team’s submissions in real time, responding to questions and … |
Daily Mail |
Scientists ‘completely CURE’ bowel cancer in mice using a form of pioneering immunotherapy and say it could kill …
Daily Mail They report they have achieved a ‘100-percent cure rate’ in mice without any treatment-related toxic effects. A US team developed a new type of radioimmunotherapy (RIT), which combines traditional radiation treatment and immunotherapy. They believe it … Cancer Immunotherapies Market trends, Prospect, Growth trend Anaysis and ForecastsatPRnews (press release) |